---
layout: default
title: Abrus Precatorius Seed Aconitum Napellus Allylthio
parent: 僅模型預測 (L5)
nav_order: 51
evidence_level: L5
indication_count: 0
---

# Abrus Precatorius Seed Aconitum Napellus Allylthio
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Combination Formula: No Repurposing Candidates Identified

## One-Sentence Summary

This Evidence Pack describes a 51-ingredient multi-component formula whose individual constituents span plant extracts, minerals, animal venoms, and food-derived substances — consistent with a homeopathic combination product.
The TxGNN model generated **no predicted indications** for this entry, likely because the compound could not be resolved to a single DrugBank or knowledge-graph node.
As a result, **no repurposing evidence, clinical trial links, or literature associations** can be presented at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established — no regulatory approvals on record |
| Predicted New Indication | None — TxGNN returned no candidates |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only) — actually below L5; no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This entry is registered under a single candidate ID (`TW-UNKNOWN-multi`) but contains **51 distinct active ingredients**, ranging from botanical extracts (Aconitum napellus, Glycyrrhiza glabra, Garlic) to mineral compounds (Arsenic trioxide, Sulfur, Phosphorus), animal-derived substances (Lachesis muta venom, Sepia officinalis juice), and common food components (Lactose, Sucrose, Saccharin).

This ingredient profile is characteristic of a **homeopathic combination product**, where each constituent is included at highly diluted potency rather than as a pharmacologically active dose. Because TxGNN's knowledge graph maps single-entity drugs (identified by a DrugBank ID) to disease nodes, a multi-ingredient entry without a unified DrugBank identifier cannot be processed by the prediction pipeline. No DrugBank ID was resolved, and accordingly no repurposing candidates were output.

A secondary concern is that several individual ingredients carry significant standalone pharmacological profiles — most notably **arsenic trioxide** (an approved antineoplastic for acute promyelocytic leukemia) and **caffeine**. However, within a homeopathic dilution context these are not equivalent to their therapeutic doses, and analyzing them individually as repurposing candidates would require separate, single-drug Evidence Pack submissions.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The current Evidence Pack cannot support a repurposing evaluation because (1) the entry is a multi-ingredient mixture that cannot be matched to a single knowledge-graph node, (2) TxGNN returned zero predicted indications, and (3) no regulatory approval, mechanism of action data, or safety information is available.

**To proceed, the following is needed:**

- **Decompose the formula**: If the intent is to evaluate a specific pharmacologically active ingredient (e.g., arsenic trioxide), submit a separate single-drug Evidence Pack for that ingredient with its own DrugBank ID.
- **Clarify product identity**: Confirm whether this is a registered homeopathic product, an investigational formulation, or a data pipeline error (e.g., multiple drugs concatenated into a single INN field).
- **Resolve DrugBank ID**: Without a valid DrugBank ID, TxGNN prediction, MOA analysis, and DDI screening cannot be performed.
- **Obtain regulatory status**: If the product exists as a finished dosage form in any jurisdiction, retrieve the registration number and package insert to establish original indication and safety profile.
- **Resubmit as individual ingredients**: For a systematic repurposing analysis, each clinically relevant component should be evaluated separately through the standard pipeline.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

